Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG) - Episode 3

Less Common Molecular Alterations in pLGG and Testing Recommendations

The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of pLGG presentation and categorization
    EP. 2: Molecular Characterization of pLGG
    Now Viewing
    EP. 3: Less Common Molecular Alterations in pLGG and Testing Recommendations
    EP. 4: Standard of care for frontline treatment of non-V600E-specific pLGG tumors
    EP. 5: Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
    EP. 6: Current Treatment of Patients with NF1 pLGG
    EP. 7: Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
    EP. 8: Treatment Considerations for Progressive pLGG
    EP. 9: Radiation and Targeted Therapies for Progressive pLGG
    EP. 10: The Role of Tovorafenib in Treatment of Progressive pLGG
    EP. 11: Clinical Trials to Increase Treatment Options in the Progressive Setting
    EP. 12: Clinical scenario 1 - BRAFKIAA-1549 fusion
    EP. 13: Alternatives and Considerations for Clinical Scenario 1
    EP. 14: Clinical Scenario 2 - BRAFV600E
    EP. 15: Potential Adverse Events With Targeted Therapies
    EP. 16: Clinical Insights: Looking Forward for pLGG
    1. Are there particular considerations depending on the type of BRAF alteration?

    x